Articles by Mark D. Tyson, MD
The panel concludes with a discussion on the complexities of interpreting ctDNA positivity in earlier-stage bladder cancer.
The panel considers the adoption of bladder-sparing protocols and the potential of biomarkers to guide risk stratification.
The panel debates the management of high-grade T1 bladder cancer with lymphovascular invasion and variant histology.
The panel pivots to complex considerations in bladder cancer treatment, weighing the promise of IO in BCG-naïve patients.
The panel shares how patient lifestyle, bladder symptoms, and other factors influence intravesical therapy selection.
The panel explores the challenges of delivering bladder-sparing therapies like gem/doce and TAR-200 in real-world settings.
The panel discusses a wave of bladder cancer therapies, including cretostimogene, gem/doce, and AI-driven biomarkers.
Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.